In pulmonary arterial hypertension, right heart function is the most important indicator of prognosis (PAH). As we will show in this post, there are currently no medicines available that directly target the right ventricle. When analysed using the pump-function graph, a meta-analysis of clinical trials in PAH found that current PAH treatment appears to have minimal cardiac-specific effects. We investigated the clinical potential of left heart failure (LHF) therapy for PAH based on currently available data, driven by the idea that "left" and "right" heart failure may share fundamental underlying pathophysiological mechanisms